Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LY007 in Relapsed/Refractory CD20+ B-NHL
NCT06364852Phase 1Recruiting
- Sponsor
- Ruijin Hospital
- Start
- Dec 2021
- Primary completion
- Aug 2024
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of LY007 in B-cell non-Hodgkin lymphoma, sponsored by Ruijin Hospital. Primary endpoints: Maximum Tolerated Dose at 2 years, Dose Limiting Toxicity at 28 days and 1 more. Started Dec 2021; status: recruiting.
02
Drugs
LY007
03
Conditions
B-cell non-Hodgkin lymphoma
Beyond the preview
Go deeper on NCT06364852.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06364852.